An unexpected case of large cell neuroendocrine carcinoma of the colon: a case report

被引:0
作者
Nnawuba, Kingsley [1 ]
Travis, Dylan [2 ]
Jensen, Hanna [3 ]
Lockwood, Blake [4 ]
机构
[1] Univ Arkansas Med Sci, Dept Internal Med, Northwest Reg Campus,1125 N Coll Ave, Fayetteville, AR 72703 USA
[2] Univ Arkansas Med Sci, Coll Med, Fayetteville, AR 72703 USA
[3] Univ Arkansas Med Sci, Dept Surg, Fayetteville, AR 72703 USA
[4] Highlands Oncol Grp, Div Hematol & Oncol, Springdale, AR USA
关键词
Large cell neuroendocrine carcinoma (LCNEC); case report; colon; CONSENSUS GUIDELINES; RECTUM;
D O I
10.21037/jgo-23-542
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Patients presenting with large cell neuroendocrine carcinomas (LCNECs) comprise a small minority of total colon and rectal cancers (1-2%) with poor prognostic outcomes in lieu of late diagnosis and metastasis at the point of diagnosis. Case Description: We report a case presentation of a 69-year-old male presenting with diffuse, non severe upper abdominal pain and a positive at-home colon cancer screening test. At the time of presentation, the patient was negative for constipation or blood in stool. The patient underwent a colonoscopy with biopsy results positive for LCNEC within the proximal ascending colon. A right hemicolectomy was performed with subsequent pathology indicating a poorly differentiated LCNEC with 4/18 positive nodes and final pathology showing stage IIIA (T3, N1, M0) with Ki-67 index at 70%. Post-operative intervention included two cycles of carboplatin and etoposide as well as routine follow-up for labs, imaging, and pharmacological management. Conclusions: LCNECs are highly aggressive with poor prognostic outcomes and high mortality rates on both 1-and 5-year survival scales. Prior studies and reports indicated a need for further research and data investigating treatment standardization for patients diagnosed with LCNECs. In lieu of this, this study provides a potential standardized treatment modality combining both European Neuroendocrine Tumor Society (ENETS) and North American Neuroendocrine Tumor Society (NANETS) consensus guidelines.
引用
收藏
页码:508 / 513
页数:6
相关论文
共 12 条
[11]   Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors [J].
Vilar, Eduardo ;
Salazar, Ramon ;
Perez-Garcia, Jose ;
Cortes, Javier ;
Oberg, Kjell ;
Tabernero, Josep .
ENDOCRINE-RELATED CANCER, 2007, 14 (02) :221-232
[12]  
Vitallonga R, 2008, REV ESP ENFERM DIG, V100, P11, DOI 10.4321/s1130-01082008000100003